The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...

When Sue Vincent was diagnosed with advanced ovarian cancer, she was told she could have just months to live - until a miracle drug changed everything ...

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast ...

LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better ...

Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial ...